SOAT1 and interstitial lung disease: While JAK inhibitors have been investigated in the context of ILD [59], and are thought to inhibit the SASP [60], it may be that the JAK/STAT pathway is not sufficiently upregulated in senescent AECs and that in this specific context, JAK inhibition is more suited to inhibiting the paracrine effects of the SASP rather than the production of the SASP components themselves.